Study of Efsubaglutide Alfa for Weight Loss in Adults Aged 18 to 55 Years Who Are Still Obese 6 Months After Metabolic Surgery

What this Trial Is About

Researchers are evaluating the effectiveness and safety of efsubaglutide alfa in adults aged 18 to 55 who remain obese six months after metabolic surgery. The study aims to see if this medication can help normalize weight and improve related health conditions, assessing its benefits for managing obesity after surgery. This phase 4 clinical trial is randomized, double-blind, and placebo-controlled. Participants are randomly assigned to one of two groups one group receives efsubaglutide alfa injections along with diet and exercise guidance, while the other group receives only diet and exercise guidance without the drug. Efsubaglutide alfa is given as a subcutaneous injection once weekly, starting at 1 mgweek for two weeks and gradually increasing to 9 mg every two weeks by week 13. The treatment period lasts 24 weeks. During the study, participants will be monitored through regular assessments including body weight, body composition, blood pressure, fasting blood glucose, and HbA1c levels. Researchers will track changes in total weight loss percentage and remission of obesity-related diseases over the 24-week study. Safety will be closely observed, and all participants will receive diet and exercise counseling throughout the trial period.

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery